A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ORG / obesity-related glomerulopathy

[Related PubMed/MEDLINE]
Total Number of Papers: 46
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ORG  (>> Co-occurring Abbreviation)
Long Form:   obesity-related glomerulopathy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Megalin - a facultative marker of obesity-related glomerulopathy in children. ---
2019 Renal-Protective Effects of the Peroxisome Proliferator-Activated Receptor-gamma Agonist Pioglitazone in ob/ob Mice. ADP, AMPK, mALB, NOX4, PPARgamma, WT1, ZO-1
2019 The spectrum of kidney biopsy findings in patients with morbid obesity. BMI, CKD, eGFR
2018 Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/beta-catenin signaling in podocytes. ALDO, DKK1
2018 Alteration of Connexin43 expression in a rat model of obesity-related glomerulopathy. Cx43
2018 Coptidis Rhizoma inhibits NLRP3 inflammasome activation and alleviates renal damage in early obesity-related glomerulopathy. 3D-HPLC, CKD, OP
2018 Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes. GLP-1, LC3, PA, PI3K
2018 Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-kappaB and ERK/p38 MAPK-dependent inflammation. HFD, LXA4, MAPKs, NF-kappaB
2018 Proteomic Analysis Reveals the Renoprotective Effect of Tribulus terrestris against Obesity-Related Glomerulopathy in Rats. HRGECs, MALDI-TOF, oxLDL
10  2018 Purinergic 2X7 Receptor is Involved in the Podocyte Damage of Obesity-Related Glomerulopathy via Activating Nucleotide-Binding and Oligomerization Domain-Like Receptor Protein 3 Inflammasome. ASC, NLRP3, P2X7R
11  2017 Kidney disease in patients with obesity: It is not always obesity-related glomerulopathy alone. ---
12  2017 Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy. MC, TGF-beta1, TNF-alpha
13  2017 Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment. ---
14  2017 The Fatty Kidney: Obesity and Renal Disease. ---
15  2016 Consequences of morbid obesity on the kidney. Where are we going? ---
16  2016 G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. DN, IDH2, SIRT1, SIRT3, SOD2
17  2016 Proteinuria rebound in IgA nephropathy associated with obesity-related glomerulopathy. IgAN, MPGN
18  2016 Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity. alpha-SMA, BMI, GFR, PCX, UPCR, VEGF
19  2015 Inhibition of mitogen-activated protein kinases/nuclear factor kappaB-dependent inflammation by a novel chalcone protects the kidney from high fat diet-induced injuries in mice. ---
20  2015 The Protective Effects of Curcumin on Obesity-Related Glomerulopathy Are Associated with Inhibition of Wnt/beta-Catenin Signaling Activation in Podocytes. ---
21  2014 Association between excess body weight and urine protein concentration in healthy dogs. BCS, UAC, UPC
22  2014 Evidence for the use of glomerulomegaly as a surrogate marker of glomerular damage and for alpha-linolenic acid-rich oils in the treatment of early obesity-related glomerulopathy in a diet-induced rodent model of obesity. ALA, LA
23  2014 Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. CKD
24  2014 Non-diabetic renal diseases in a multi-ethnic New Zealand cohort with type 2 diabetes mellitus: clinical and histopathological features. DN, eGFR, FSGS, NDRD
25  2014 Two children with obesity-related glomerulopathy identified in a school urinary screening program. BMI, SUS
26  2013 Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy. ---
27  2013 Dietary linoleic acid and alpha-linolenic acid differentially affect renal oxylipins and phospholipid fatty acids in diet-induced obese rats. ALA, LA, PUFAs
28  2013 Lipid mediators of inflammation in obesity-related glomerulopathy. CKD
29  2013 Medaka fish, Oryzias latipes, as a model for human obesity-related glomerulopathy. HFD, HFD
30  2013 Obesity-related glomerulopathy and the nephron complement. ---
31  2013 Roles of mast cells and monocyte chemoattractant protein-1 in the renal injury of obesity-related glomerulopathy. ---
32  2013 Urogenital complications of obesity. ---
33  2012 Heart-type fatty acid binding protein is associated with proteinuria in obesity. HDL, HOMA-IR
34  2012 Obesity-related glomerulopathy and podocyte injury: a mini review. PAI-1
35  2011 Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis. FSGS
36  2011 Evaluation of metabolic risk marker in obesity-related glomerulopathy. HOMA-IR
37  2010 Metabolic syndrome risk factors and estimated glomerular filtration rate among children and adolescents. BMI, eGFR, HDL, LDL, MAP, SBP
38  2010 Obesity-related glomerulopathy: body mass index and proteinuria. BMI
39  2009 Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. ACEI, ARB, FSGS
40  2008 Obesity-related glomerulopathy in China: a case series of 90 patients. BMI, Ccr, FSGS
41  2008 The relationship between body fat distribution and renal damage in Chinese with obesity. ---
42  2007 Amylin deposition in the kidney of patients with diabetic nephropathy. DN
43  2006 Epidemiology of obesity and chronic kidney disease. CKD
44  2006 Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. ---
45  2004 [Overweight and obesity--risk factors in the development and progression of renal disease]. ---
46  2001 Obesity-related glomerulopathy: an emerging epidemic. ACE, BMI, I-FSGS